Prostate Cancer News on BioPortfolio

UK Team to Lead Innovative European Prostate Cancer Programme

The University of Glasgow will lead an innovative PanEuropean research training program targeting incurable prostate cancer. The fouryear Translational Research Network for Prostate Cancer TransPot aims to provide a multidisciplinary training program integ...

Evolutionary history of tumor helps predict severity of prostate cancer

Findings from Canadian Prostate Cancer Genome Network CPCGENE researchers and their collaborators published today in Cell show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumor has evolved. Thi...

Hardman & Co Research ValiRx VAL 2017 a pivotal year

Hardman & Co Research20Apr2018 1043 GMTBSTHardman & Co Research 2017 a pivotal yearValiRx VAL is a clinicalstage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading assets...

Landmark study links tumour evolution to prostate cancer severity

Findings from Canadian Prostate Cancer Genome Network CPCGENE researchers and their collaborators published today in Cell show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has...

MDxHealth R SelectMDx Included in Dutch DRG Reimbursement System

NEWS RELEASE                                            ÂÂFurther progress of strategy to expand market for SelectMDx IRVINE CA and HERSTAL BELGIUM 0700 CEST April 20 2018 MDxHealth SA "MDxHealth...

Seed funding for biomedical projects

Four clinically led biomedical engineering projects have received seed funding from the UNSW faculties of Medicine and Engineering.UNSW is investing up to $1.8 million on projects that engage clinicians in solving problems such as sleep apnoea keeping the ...

Landmark study links tumor evolution to prostate cancer severity

Ontario Institute for Cancer Research Findings from Canadian Prostate Cancer Genome Network CPCGENE researchers and their collaborators published today in Cell show that the aggressiveness of an individual prostate cancer can be accurately assessed by look...

ASCO Issues New Metastatic Prostate Cancer Treatment Guide

Adding docetaxel or abiraterone to ADT improves metastatic prostate cancer survival with patient and cost factors the most important considerations when choosing between them say guidelines. Medscape Medical News

LowDose Prostate Drug Can Match Standard Dose Cut Costs

Patients who cannot afford to take abiraterone acetate for metastatic castrationresistant prostate cancer could benefit just as much from taking just a quarter dose with food say US researchers. Medscape Medical News

Pages